Chronic Kidney Disease(CKD)NCT06819527
Medication Reconciliation in Hospitalized CKD Patients : A Quasi-Experimental Study
A study testing Medication reconciliation service in people with Chronic Kidney Disease(CKD), run by Jordan University of Science and Technology at 1 site in Jordan.
Trial summary
This study aimed to evaluate the impact of combining medication reconciliation with medication review on reducing medication discrepancies at discharge and all-cause readmissions among CKD patients, in comparison to a retrospective control group that received usual care, which may or may not have included medication… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Chronic Kidney Disease(CKD)
- What is being tested?
- Medication reconciliation service
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 323 participants
- Where
- 1 siteJordan
- Study dates
- 1 Feb 2023to 30 Aug 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult (18 years or older) admitted patients with CKD (stages 2-5 ), who were using at least three chronic medicines at home, and were hospitalized for at least 48 hours.
Who cannot join
- Patients with kidney transplantation .
- Patients who have difficulties in responding to interviews and did not have family member or caregiver on behave.
- Patients who refused to provide a written informed consent.
Trial locations and contacts
1 site in 1 country.
Jordan1 site
King Abdullah University Hospital and Princess Basma Hospital
Irbid, 22110
About this study
Official title: The Impact of Medication Reconciliation on Discrepancies and All-cause Readmission Among Hospitalized Patients With Chronic Kidney Disease: A Quasi-experimental Study
This study aimed to evaluate the impact of combining medication reconciliation with medication review on reducing medication discrepancies at discharge and all-cause readmissions among CKD patients, in comparison to a retrospective control group that received usual care, which may or may not have included medication reconciliation.
- Conditions
- Chronic Kidney Disease(CKD)
- Being tested
- Medication reconciliation service
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Medication reconciliation serviceOther
Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | interventional group, in which patients received a supplemented medication reconciliation service. Receives: Other: Medication reconciliation service |
| Retrospective control group in which patients received the usual care | No intervention | A retrospective control group in which patients received the usual care that may or may not include medication reconciliation |
What is being measured
The primary outcome is the main question the study is designed to answer.
all-cause 90-day readmission
The primary outcome in this study was the likelihood of all-cause 90-day readmission as extracted from medical records for both study groups
Measured: 90 days after discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2025
- Study start1 Feb 2023
- Primary completion30 Aug 2023
- Study completion30 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Kidney Disease(CKD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- This was a quasi-experimental trial
- Masking
- None (open label)
- Enrolment
- 323 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jordan University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06819527
- Sponsor's protocol ID
- Grant number: 20220257
- Status last verified
- Jan 2026
- First submitted
- 5 Feb 2025
- Last updated
- 29 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publications
Abu Farha R, Yousef A, Gharaibeh L, Alkhalaileh W, Mukattash T, Alefishat E. Medication discrepancies among hospitalized patients with hypertension: assessment of prevalence and risk factors. BMC Health Serv Res. 2021 Dec 14;21(1):1338. doi: 10.1186/s12913-021-07349-5.
PubMed 34903221
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Medication Reconciliation on Discrepancies and All-cause Readmission Among Hospitalized Patients With Chronic Kidney Disease: A Quasi-experimental Study
- ClinicalTrials.gov ID
- NCT06819527
- Acronym / sponsor ID
- Grant number: 20220257
- Conditions
- Chronic Kidney Disease(CKD)
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 323 participants (actual)
- Lead sponsor
- Jordan University of Science and TechnologyUniversity, hospital or other
- Study start
- 1 Feb 2023 (actual)
- Primary completion
- 30 Aug 2023 (actual)
- Study completion
- 30 Aug 2023 (actual)
- First posted
- 11 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to evaluate the impact of combining medication reconciliation with medication review on reducing medication discrepancies at discharge and all-cause readmissions among CKD patients, in comparison to a retrospective control group that received usual care, which may or may not have included medication reconciliation.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This was a quasi-experimental trial
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Other: Medication reconciliation serviceinterventional group, in which patients received a supplemented medication reconciliation service. |
| Retrospective control group in which patients received the usual care | No intervention | –A retrospective control group in which patients received the usual care that may or may not include medication reconciliation |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adult (18 years or older) admitted patients with CKD (stages 2-5 ), who were using at least three chronic medicines at home, and were hospitalized for at least 48 hours.
Key exclusion criteria (3 listed)
- Patients with kidney transplantation .
- Patients who have difficulties in responding to interviews and did not have family member or caregiver on behave.
- Patients who refused to provide a written informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Medication reconciliation servicePatients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions. | Other | Intervention group |
Primary outcome
all-cause 90-day readmission
Time frame: 90 days after discharge
The primary outcome in this study was the likelihood of all-cause 90-day readmission as extracted from medical records for both study groups
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2026.
- Background: PubMed 34903221Abu Farha R, Yousef A, Gharaibeh L, Alkhalaileh W, Mukattash T, Alefishat E. Medication discrepancies among hospitalized patients with hypertension: assessment of prevalence and risk factors. BMC Health Serv Res. 2021 Dec 14;21(1):1338. doi: 10.1186/s12913-021-07349-5.
- Individual participant dataSharing planned: No. The data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Related trials for Chronic Kidney Disease(CKD)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
RecruitingObservational study
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Medication reconciliation service in people with Chronic Kidney Disease(CKD), run by Jordan University of Science and Technology at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
all-cause 90-day readmission (time frame: 90 days after discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06819527, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.